Therapeutic compounds and uses thereof

1. A compound having a structure according to Formula I or II:

wherein,

ring A is a saturated or partially saturated five to seven membered heterocyclic ring, or a five to seven membered heteroaryl ring, containing one or more hetero atoms independently selected from —O—, —N—, and —S—;

ring B is a saturated or partially saturated five to seven membered heterocyclic ring, or a five to seven membered heteroaryl ring, containing one or more hetero atoms independently selected from —O—, —N—, and —S—, wherein ring B is attached to the remainder of the molecule via a ring carbon;

R1 is attached to a B-ring heteroatom and is selected from H, C 1-6 alkyl, branched C 1-6 alkyl, formyl, acetyl, carboxylate, carboxamide, a natural or unnatural amino acid, D- or L-lactic acid, and hydroxy acetic acid;

R2 and R3 are independently selected from H, halo, C 1-6 alkyl, C 1-6 alkoxy, acyl, sulfonyl, sulfamoyl, sulfonate, carboxylic acid, ester, carboxamide, and cycloalkyl;

n is 0, 1, 2, 3, 4, or 5; and

R5 is selected from F, Cl, Br, I, CF 3 , NO 2 , CN, CH 2 NH 2 , CH 2 NHCH 3 , CH 2 NMe 2 , —CO 2 CH 3 , CO 2 C 2 H 5 , —NHCH 3 , and —NMe 2 ;

and pharmaceutically acceptable salts thereof.

2. A compound of claim 1 having a structure according to Formula I wherein n, rings A and B, and substituents R1 and R5, are as defined in claim 1 .

3. A compound of claim 1 having a structure according to Formula II wherein n, ring B, and substituents R1, R2, R3 and R5, are as defined in claim 1 .

4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

5. A compound of claim 1 , wherein n is 1, 2, or 3 and R5 is selected from F, Cl, Br, I, CF 3 , NO 2 , —NMe 2 , and CN.

6. A compound of claim 1 , wherein ring B is a piperidine, pyrrolidine, homopiperidine, or thiophene ring.

7. A compound of claim 1 , wherein R1 is:

8. A compound of claim 1 , having a structure according to Formula I, wherein the A ring is a fused, 5 or 6 membered ring, containing one or two oxygens.

9. A compound of claim 1 , further having a structure according to Formula IV:

wherein,

n is 1, 2, or 3;

m is 1 or 2;

p is 0, 1, or 2;

R1 is selected from H, C 1-6 alkyl, branched C 1-6 alkyl, formyl, acetyl, carboxylate, carboxamide, a natural or unnatural amino acid, D- or L-lactic acid, and hydroxy acetic acid; and

R5 is selected from F, Cl, Br, I, CF 3 , NO 2 , —NMe 2 , and CN.

10. A compound of claim 9 , wherein R5 is selected from —NMe 2 , F, Cl, Br, or I.

11. A compound of claim 9 , wherein R1 is:

12. A compound of claim 1 , further having a structure according to Formula V:

wherein,

n is 1, 2, or 3;

ring B is a saturated or partially saturated five to seven membered heterocyclic ring, or a five to seven membered heteroaryl ring, containing one or more heteroatoms independently selected from —O—, —N—, and —S—, wherein ring B is attached to the remainder of the molecule via a ring carbon;

R1 is selected from H, C 1-6 alkyl, branched C 1-6 alkyl, formyl, acetyl, carboxylate, carboxamide, a natural or unnatural amino acid, D- or L-lactic acid, and hydroxy acetic acid; and

R4 is selected from H, halo, C 1-6 alkyl, C 1-6 alkoxy, acyl, sulfonyl, sulfamoyl, sulfonate, carboxylic acid, ester, carboxamide, and cycloalkyl; and

R5 is selected from F, Cl, Br, I, CF 3 , NO 2 , —NMe 2 , and CN.

13. A compound of claim 1 , further having a structure according to Formula VI:

wherein,

n is 1, 2, or 3;

p is 0, 1, or 2;

R1 is selected from H, C 1-6 alkyl, branched C 1-6 alkyl, formyl, acetyl, carboxylate, carboxamide, a natural or unnatural amino acid, D- or L-lactic acid, and hydroxy acetic acid; and

R4 is selected from H, halo, C 1-6 alkyl, C 1-6 alkoxy, acyl, sulfonyl, sulfamoyl, sulfonate, carboxylic acid, ester, carboxamide, and cycloalkyl; and

R5 is selected from F, Cl, Br, I, CF 3 , NO 2 , —NMe 2 , and CN.

14. A compound of claim 13 , wherein R5 is selected from —NMe 2 , F, Cl, Br, or I.

15. A compound of claim 13 , wherein R1 is:

16. A compound of claim 13 , wherein R4 is C 1-6 alkoxy.

17. A method of making a compound having a structure according to Formula I or II:

wherein,

ring A is a saturated or partially saturated five to seven membered heterocyclic ring, or a five to seven membered heteroaryl ring, containing one or more hetero atoms independently selected from —O—, —N—, and —S—;

ring B is a saturated or partially saturated five to seven membered heterocyclic ring, or a five to seven membered heteroaryl ring, containing one or more hetero atoms independently selected from —O—, —N—, and —S—, wherein ring B is attached to the remainder of the molecule via a ring carbon;

R1 is attached to a B-ring heteroatom and is selected from H, C 1-6 alkyl, branched C 1-6 alkyl, formyl, acetyl, carboxylate, carboxamide, a natural or unnatural amino acid, D- or L-lactic acid, and hydroxy acetic acid;

R2 and R3 are independently selected from H, halo, C 1-6 alkyl, C 1-6 alkoxy, acyl, sulfonyl, sulfamoyl, sulfonate, carboxylic acid, ester, carboxamide, and cycloalkyl;

n is 0, 1, 2, 3, 4, or 5; and

R5 is selected from F, Cl, Br, I, CF 3 , NO 2 , CN, CH 2 NH 2 , CH 2 NHCH 3 , CH 2 NMe 2 , —CO 2 CH 3 , CO 2 C 2 H 5 , —NHCH 3 , and —NMe 2 ;

and pharmaceutically acceptable salts thereof;

said method of making comprising:

reacting

 with either

 wherein X is a halogen, to form either intermediate A

 or intermediate B

 respectively;

deprotecting either intermediate A or intermediate B to form either intermediate C

 or intermediate D

 respectively;

reacting either intermediate C or intermediate D with

 wherein LG is a leaving group, to form a compound having a structure according to Formula I or Formula II, respectively.

18. The method of claim 17 , wherein said LG is selected from acetate, p-nitrobenzoate, sulfonates, methanesulfonate, p-toluenesulfonate, p-bromobenzenesulfonate, p-nitrobenzenesulfonate, fluoromethanesulfonate, difluoromethanesulfonate, trifluoromethanesulfonate, ethanesulfonate, halogens, iodine, bromine, and chlorine and reacting either intermediate C or intermediate D with

is performed under suitable conditions.

19. The method of claim 18 , wherein reacting

with either

comprises utilizing a copper or palladium catalyzed coupling under suitable conditions and wherein X is iodine or bromine.

20. The method of claim 19 , wherein deprotecting either intermediate A or intermediate B to form either intermediate C

or intermediate D

respectively, comprises dissolving either intermediate A or intermediate B is trifluoracetic acid under suitable conditions.